A. Petros

发表

Development of Orally Efficacious Allosteric Inhibitors of TNFα via Fragment-Based Drug Design.

S. C. Panchal, Philip B. Cox, P. Hajduk, 2020, Journal of medicinal chemistry.

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

S. Korsmeyer, A. Letai, P. Hajduk, 2005, Nature.

Discovery and Design of Novel HSP90 Inhibitors Using Multiple Fragment‐based Design Strategies

Jean M. Severin, P. Hajduk, J. R. Huth, 2007, Chemical biology & drug design.

Rationale for Bcl‐XL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies

A. Petros, R. Meadows, E. Olejniczak, 2000, Protein science : a publication of the Protein Society.

Structural biology of the Bcl-2 family of proteins.

A. Petros, E. Olejniczak, S. Fesik, 2004, Biochimica et biophysica acta.

Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis.

P. Hajduk, A. Petros, S. Fesik, 2006, Journal of medicinal chemistry.

Conformation of an FK506 analog in aqueous solution is similar to the FKBP-bound conformation of FK506

A. Petros, S. Fesik, Heng Liang, 1993 .

Targeting lysine specific demethylase 4A (KDM4A) tandem TUDOR domain - A fragment based approach.

A. Petros, Chaohong Sun, R. Henry, 2018, Bioorganic & medicinal chemistry letters.

Defining the p53 DNA‐binding domain/Bcl‐xL‐binding interface using NMR

A. Gunasekera, A. Petros, E. Olejniczak, 2004, FEBS letters.

Backbone dynamics of a two-domain protein: 15N relaxation studies of the amino-terminal fragment of urokinase-type plasminogen activator.

A. Petros, R. Meadows, S. Fesik, 1994, Biochemistry.

Characterization of a posttranslational fucosylation in the growth factor domain of urinary plasminogen activator.

A. Petros, E. Zuiderweg, A. Buko, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.

A. Petros, S. Fesik, S. Ng, 2006, Journal of medicinal chemistry.

Discovery of novel inhibitors of Bcl-xL using multiple high-throughput screening platforms.

J. R. Huth, A. Petros, K. Comess, 2004, Analytical biochemistry.

Discovery and optimization of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of albumin binding.

Scott A. Erickson, S. Davidsen, A. Petros, 2006, Journal of medicinal chemistry.

Analysis of the aromatic 1H NMR spectrum of chicken plasminogen kringle 4.

A. Petros, M. Llinás, L. Patthy, 1988, Archives of biochemistry and biophysics.

Proton magnetic resonance study of lysine-binding to the kringle 4 domain of human plasminogen. The structure of the binding site.

A. Petros, M. Llinás, A. Tulinsky, 1987, Journal of molecular biology.

Synthesis and FKBP binding of small molecule mimics of the tricarbonyl region of FK506

A. Petros, S. Fesik, Gary T. Wang, 1994 .

Multidimensional NMR studies of immunosuppressants and their binding proteins

A. Petros, Y. Thériault, T. Logan, 1993 .

Domain analysis of urokinase plasminogen activator (u-PA): Preparation and characterization of intact A-chain molecules

A. Petros, A. Mazar, J. Henkin, 1992 .

Identification and structure-based drug design of cell-active inhibitors of interleukin 17A at a novel C-terminal site

Justin D Dietrich, A. Petros, P. Richardson, 2022, Scientific Reports.

Solution structure of the DNA-binding domain of a human papillomavirus E2 protein: evidence for flexible DNA-binding regions.

A. Petros, D. Egan, R. Meadows, 1996, Biochemistry.

Identification of solvent-exposed regions of an FK-506 analog, ascomycin, bound to FKBP using a paramagnetic probe

A. Petros, S. Fesik, P. Neri, 1992, Journal of biomolecular NMR.

Turning a Substrate Peptide into a Potent Inhibitor for the Histone Methyltransferase SETD8.

A. Petros, Chaohong Sun, M. Vedadi, 2016, ACS medicinal chemistry letters.

Design, synthesis, and computational studies of inhibitors of Bcl-XL.

A. Petros, Cheol‐Min Park, R. Henry, 2006, Journal of the American Chemical Society.

Correction to Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity.

Scott A. Erickson, C. Tse, A. Petros, 2015, Journal of medicinal chemistry.

Divergence of Genbank and human tumor Bcl-2 sequences and implications for binding affinity to key apoptotic proteins

A. Petros, R. Simmer, S. Ng, 2004, Oncogene.

Analysis of ligand-binding to the kringle 4 fragment from human plasminogen

A. Petros, M. Llinás, R. Laursen, 2004, European Biophysics Journal.

1H NMR studies of aliphatic ligand binding to human plasminogen kringle 4.

A. Petros, M. Llinás, V. Ramesh, 1989, Biochemistry.

Nuclear magnetic resonance methods for studying protein-ligand complexes.

A. Petros, S. Fesik, 1994, Methods in enzymology.

Novel inhibitors of Erm methyltransferases from NMR and parallel synthesis.

P. Hajduk, A. Petros, S. Fesik, 1999, Journal of medicinal chemistry.

Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.

Mary K Joseph, Saul H Rosenberg, Xiaohong Song, 2007, Journal of medicinal chemistry.

Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors.

A. Petros, Chaohong Sun, P. Kovar, 2017, Journal of medicinal chemistry.

Structure and ligand recognition of the phosphotyrosine binding domain of Shc

A. Petros, R. Meadows, E. Olejniczak, 1995, Nature.

NMR studies of an FK-506 analog, [U-13C]ascomycin, bound to FK-506-binding protein.

A. Petros, E. Olejniczak, S. Fesik, 1992, Journal of medicinal chemistry.

A practical method for uniform isotopic labeling of recombinant proteins in mammalian cells.

A. Petros, S. Fesik, A. Mazar, 1992, Biochemistry.

Solution structure of the antiapoptotic protein bcl-2

A. Petros, S. Fesik, H. Yoon, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Discovery and development of potent and selective inhibitors of histone methyltransferase g9a.

C. Tse, A. Petros, N. Soni, 2014, ACS medicinal chemistry letters.

The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.

Jun Guo, Kenneth M Comess, Haizhong Zhu, 2017, Nature chemical biology.

A Surface Groove Essential for Viral Bcl-2 Function During Chronic Infection In Vivo

A. Petros, E. Olejniczak, H. Virgin, 2005, PLoS pathogens.

Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.

Scott A. Erickson, C. Tse, A. Petros, 2015, Journal of medicinal chemistry.

Solution structure of a Bcl-2 homolog from Kaposi sarcoma virus

A. Petros, E. Olejniczak, S. Fesik, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Ligand-binding effects on the kringle 4 domain from human plasminogen: a study by laser photo-CIDNP 1H-NMR spectroscopy.

A. Petros, R. Kaptein, R. Boelens, 1989, Biochimica et biophysica acta.

Solution structure of a pleckstrin-homology domain

P. Hajduk, A. Petros, R. Meadows, 1994, Nature.

Fragment-Based Discovery of an Apolipoprotein E4 (apoE4) Stabilizer.

Justin D Dietrich, A. Petros, V. Stoll, 2019, Journal of medicinal chemistry.

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.

Brian J. Smith, C. Tse, A. Petros, 2014, ACS medicinal chemistry letters.

Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator.

A. Petros, R. Meadows, E. Olejniczak, 1994, Biochemistry.

Solution structure of the BHRF1 protein from Epstein-Barr virus, a homolog of human Bcl-2.

A. Petros, E. Olejniczak, S. Fesik, 2003, Journal of molecular biology.

Identification of protein surface residues by 2D NMR

A. Petros, K. Kopple, 1991 .

NMR identification of protein surfaces using paramagnetic probes.

L. Mueller, A. Petros, K. Kopple, 1990, Biochemistry.

NMR studies of protein surfaces. The interaction of lysozyme with tri-N-acetylglucosamine.

A. Petros, K. Kopple, 1990, Biochemical pharmacology.

Three-dimensional structure of the FK506 binding protein/ascomycin complex in solution by heteronuclear three- and four-dimensional NMR.

A. Petros, R. Meadows, E. Olejniczak, 1993, Biochemistry.

Structure of the N-terminal RNA-binding domain of the SARS CoV nucleocapsid protein.

A. Gunasekera, P. Hajduk, A. Petros, 2004, Biochemistry.

Solution structure of an rRNA methyltransferase (ErmAM) that confers macrolide-lincosamide-streptogramin antibiotic resistance

Jean M. Severin, A. Petros, Liping Yu, 1997, Nature Structural Biology.

Fragment-based lead discovery: challenges and opportunities

Philip J. Hajduk, Andrew M. Petros, Chaohong Sun, 2011, J. Comput. Aided Mol. Des..

NMR-based fragment screening and lead discovery accelerated by principal component analysis

A. Petros, Chaohong Sun, S. V. Van Doren, 2019, Journal of Biomolecular NMR.

N-aryl-benzimidazolones as novel small molecule HSP90 inhibitors.

Jun Chen, Saul H Rosenberg, Xiaohong Song, 2010, Bioorganic & medicinal chemistry letters.

High-level expression of recombinant human FK-binding protein from a fusion precursor

Jean M. Severin, N. Burres, A. Petros, 1992, Journal of protein chemistry.

Conformation of two non‐immunosuppressive FK506 analogs when bound to FKBP by isotope‐filtered NMR

A. Petros, S. Fesik, J. Luly, 1992, FEBS letters.

Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR.

Renaldo Mendoza, Saul H Rosenberg, Cheol-Min Park, 2010, Bioorganic & medicinal chemistry letters.

Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein.

Chang Park, S. Swann, A. Petros, 2014, Bioorganic & medicinal chemistry letters.

Labeled Ligand Displacement: Extending NMR-Based Screening of Protein Targets.

P. Hajduk, S. Swann, A. Petros, 2010, ACS Medicinal Chemistry Letters.

Cracking the molecular weight barrier: fragment screening of an aminotransferase using an NMR-based functional assay.

Walter F. Leise, A. Petros, Chaohong Sun, 2011, Bioorganic & medicinal chemistry letters.

Methylpyrrole inhibitors of BET bromodomains.

A. Petros, Chaohong Sun, N. Soni, 2017, Bioorganic & medicinal chemistry letters.

Insights into the conformation and self-association of a concentrated monoclonal antibody using isothermal chemical denaturation and nuclear magnetic resonance.

A. Petros, Chaohong Sun, C. Radziejewski, 2021, Journal of pharmaceutical sciences.

Kringle 4 from human plasminogen: a proton magnetic resonance study via two-dimensional photochemically induced dynamic nuclear polarization spectroscopy.

A. Petros, R. Kaptein, R. Boelens, 1986, Biochemistry.

Ligand binding to domain-3 of human serum albumin: a chemometric analysis

Yvonne C. Martin, Mark G. Bures, Jeffrey R. Huth, 2003, J. Comput. Aided Mol. Des..

14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation.

S R Datta, M E Greenberg, Alexander Y Katsov, 2000, Molecular cell.

Fragment-Based Drug Discovery: A Practical Approach

Philip J. Hajduk, Andrew M. Petros, P. Hajduk, 2009 .

Analysis of the aliphatic 1H-NMR spectrum of plasminogen kringle 4. A comparative study of human, porcine, bovine and chicken homologs.

A. Petros, M. Llinás, L. Patthy, 1988, European journal of biochemistry.

Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors.

A. Petros, P. Kovar, Chang H. Park, 2017, Journal of medicinal chemistry.

Fragment-based discovery of a potent NAMPT inhibitor.

K. Longenecker, A. Petros, R. Clark, 2017, Bioorganic & medicinal chemistry letters.

Optimized constant-time 4D HNCAHA and HN(CO)CAHA experiments. Applications to the backbone assignments of the FKBP/ascomycin complex

A. Petros, E. Olejniczak, S. Fesik, 1992 .

Four-dimensional [13C,1H,13C,1H] HMQC-NOE-HMQC NMR spectroscopy: resolving tertiary nuclear Overhauser effect distance constraints in the spectra of larger proteins

A. Petros, E. Olejniczak, S. Fesik, 1991 .

Methylpyrrole inhibitors of BET bromodomains.

A. Petros, N. Soni, P. Kovar, 2017, Bioorganic & medicinal chemistry letters.

The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.

Mikkel A. Algire, Justin D Dietrich, A. Petros, 2017, Nature chemical biology.